Du är här

2014-04-24

Oxford Immunotec: Oxford Immunotec Schedules First Quarter 2014 Earnings Release and Conference Call for May 6, 2014

---------------------------------------------------------------------------------
|OXFORD, United Kingdom and MARLBOROUGH, Mass., April 24, 2014 (GLOBE NEWSWIRE) |
|-- Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to |
|release first quarter 2014 financial results prior to market open on Tuesday, |
|May 6, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick |
|Altieri, Chief Financial Officer, will host a conference call to review the |
|Company's results at 8:00 a.m. Eastern Time the same day. The call will be |
|concurrently webcast. |
| |
| |
|To listen to the conference call on your telephone, please dial (855) 363-5047 |
|for United States callers or +1 (484) 365-2897 for international callers and |
|reference confirmation code 34958334 approximately ten minutes prior to start |
|time. To access the live audio webcast or subsequent archived recording, |
|visit the Investor Relations section of Oxford Immunotec's website |
|athttp://www.oxfordimmunotec.com. The replay will be available on the |
|Company's website for approximately 90 days. |
| |
| |
|About Oxford Immunotec |
| |
| |
| |
|Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company |
|committed to improving patient care by providing advanced, innovative tests |
|in the field of immunology. The proprietary T-SPOT®technology platform |
|measures the responses of specific immune cells, known as T cells, to inform |
|the diagnosis, prognosis and monitoring of patients with immunologically |
|controlled diseases. T cells are a central component of the human body's |
|immune system, and are implicated in the control and progression of many |
|medical conditions, including certain types of infectious diseases, cancers |
|and autoimmune diseases. The Company's initial product developed using the |
|T-SPOT technology platform is the T-SPOT.TB |
|test, which is used to test for latent tuberculosis infection. The T-SPOT.TB |
|test has been approved for sale in over 50 countries, including the United |
|States, where it has received pre-market approval from the Food and Drug |
|Administration, Europe, where it has obtained a CE mark, as well as Japan and |
|China. The Company is headquartered near Oxford, UK and in Marlborough, MA. |
|Additional information can be found atwww.oxfordimmunotec.com. |
| |
| |
|T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. |
| |
|For Media Inquiries: |
| |
|Caroline Crawley |
| |
|Oxford Immunotec |
|Tel: +44 1235 442796 |
|ccrawley@oxfordimmunotec.com |
| |
| |
|For Investor Inquiries: |
| |
|Rick Altieri |
| |
|Chief Financial Officer |
|Oxford Immunotec |
|Tel: +1 (508) 481-4648 |
|raltieri@oxfordimmunotec.com |
| |
| |
|Mark Klausner |
|Westwicke Partners |
|Tel: +1 (443) 213-0500 |
|oxfordimmunotec@westwicke.com |
---------------------------------------------------------------------------------

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

HUG#1779861

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.